Lexeo Therapeutics (LXEO) Cash & Equivalents (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Cash & Equivalents data on file, last reported at $71.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 148.22% year-over-year to $71.8 million; the trailing twelve-month figure through Mar 2026 stood at $71.8 million (up 148.22% YoY), and the FY2025 full-year result was $63.0 million, up 79.93% from the prior year.
• Cash & Equivalents grew to $71.8 million in Q1 2026, from $63.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $195.1 million in Q1 2024 to a low of $28.9 million in Q1 2025.
• A 5-year average of $87.0 million and a median of $71.8 million in 2026 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 342.89% in 2024 and slumped 85.18% in 2025, its largest moves.
• Tracing LXEO's Cash & Equivalents over 5 years: stood at $77.3 million in 2022, then surged by 57.06% to $121.5 million in 2023, then tumbled by 71.17% to $35.0 million in 2024, then soared by 79.93% to $63.0 million in 2025, then gained by 13.92% to $71.8 million in 2026.
• Business Quant data shows LXEO's Cash & Equivalents at $71.8 million in Q1 2026, $63.0 million in Q4 2025, and $41.0 million in Q3 2025.